SCHEMBL5458492

SCHEMBL5458492

NC(=O)c1c(NC(=O)c2ccc(F)cc2F)sc2c(Cl)c(O)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
TDP1 Q9NUW8 1/20 0.42
SNCA P37840 2/20 0.42
P2RX1 P51575 2/20 0.39
ANO1 Q5XXA6 2/20 0.38
ANO2 Q9NQ90 1/20 0.38
F10 P00742 1/20 0.38
LMNA P02545 2/20 0.37
KCNMA1 Q12791 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
TP53 P04637 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458431 0.83 FLT3 (0.45) NPC1RAB9AKCNMA1ALDH1A1TP53
SCHEMBL5466113 0.80 FLT3 (0.42) NPC1RAB9AKCNMA1KDM4EALDH1A1
SCHEMBL5445078 0.79 CFTR (0.46) NPC1RAB9ATAS1R3TAS1R1TAS1R2
SCHEMBL5455848 0.79 KMT2A (0.43) NPC1RAB9AP2RX1LMNAKDM4E
SCHEMBL5456366 0.78 FLT3 (0.52) NPC1RAB9AANO1KDM4EALDH1A1
SCHEMBL5450952 0.77 RHOC (0.42) P2RX1P2RX4P2RX7
SCHEMBL5460181 0.76 GRIN2C (0.44) NPC1RAB9AP2RX1LMNAALDH1A1
SCHEMBL5455924 0.75 FLT3 (0.54) NPC1RAB9ATDP1LMNAKDM4E
SCHEMBL5447561 0.75 FLT3 (0.43) NPC1RAB9ALMNAKDM4EALDH1A1
SCHEMBL5447136 0.73 FLT3 (0.44) NPC1RAB9ALMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 NPC1 2627/4885RAB9A 948/4885TAS1R3 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.